Coronavirus researchers are crafting drug cocktails with Gilead's antiviral remdesivir, tapping the HIV playbook to fight the coronavirus
The key will be crafting the right cocktail of medications, testing additional drugs in combination with the antiviral remdesivir, COVID-19 researchers told Business Insider.
Remdesivir's use should help free up hospital beds, intensive care units, and ventilators as patients recover faster on the drug. But the real advantage will be its potential to serve as a backbone in combination studies, Gold said. "Those are critical trials, and I think will be coming in the relatively near term," said Badley, who chairs Mayo's COVID-19 research task force.Remdesivir will be tested in combination with an arthritis drug
Bell said he is most excited about combination trials where each of the drugs can treat distinct phases of the disease.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Coronavirus treatment: Gilead says positive data on remdesivir coming - Business InsiderOne of the most promising coronavirus treatment candidates succeeded in a late-stage trial in COVID-19 patients, Gilead said Wednesday.
Read more »
What to watch today: Dow set to jump on positive data on possible Gilead coronavirus treatmentDow futures soar on positive data about a possible Gilead Sciences coronavirus treatment.
Read more »
Gilead reports 'positive data' on remdesivir coronavirus drug trial
Read more »
Gilead Says Trial Of Antiviral Remdesivir Shows ‘Positive Data’ In Coronavirus PatientsAdditional details are expected later Wednesday.
Read more »
Gilead says early results of coronavirus drug trial show improvement with shorter remdesivir treatmentGilead says preliminary results of a coronavirus drug trial showed at least 50% of patients treated with a 5-day dosage of remdesivir improved, and more than half were discharged from the hospital within 2 weeks.
Read more »
Stocks jump as investors weigh Gilead coronavirus treatment, GDP dataU.S. stocks rebounded Wednesday as upbeat data on coronavirus treatment from Gilead Sciences offset fresh figures that showed U.S. economic growth contracted more than expected in the first quarter.
Read more »